Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1510391
European Journal of Endocrinology, Vol 151, Issue 3, 391-396
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chatzistamou, I
Right arrow Articles by Koutselini, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chatzistamou, I
Right arrow Articles by Koutselini, H
Articles

Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers

I Chatzistamou, AV Schally, H Kiaris, E Politi, J Varga, G Kanellis, A Kalofoutis, A Pafiti, and H Koutselini

Department of Pathology, Aretaieion University Hospital, Athens 115 27, Greece.

OBJECTIVE: GHRH is secreted by the hypothalamus and, upon binding to specific GHRH receptors in the pituitary, stimulates growth hormone (GH) production and release from the pituitary. In addition to this neuroendocrine action, accumulated evidence implies additional roles for GHRH in carcinogenesis in non-pituitary tissues. In vitro and in vivo studies have shown that splice variant 1 (SV1) of the GHRH receptor, which is widely expressed in non-pituitary tissues and cancers, can mediate the proliferative effects of GHRH. The aim of the present study was to investigate the operation of an autocrine stimulatory loop between GHRH and SV1 in primary breast tumors. DESIGN: Fifty-three primary breast tumors were evaluated for GHRH and SV1 expression. METHODS: Expression of GHRH and SV1 was assessed by immunohistochemistry using anti-GHRH SV95 and anti-SV1 2317/5 polyclonal antibodies. RESULTS: About 40% of the specimens tested express GHRH and/or SV1 (approx. 25% each), while in 35% of these positive specimens co-expression of these antigens was detected (P<0.01). Furthermore, a correlation of GHRH, but not SV1, expression was detected in lobular compared with ductal carcinomas. CONCLUSIONS: These results constitute the first demonstration for the expression of GHRH and SV1 in primary breast cancers, and provide evidence for the operation of an autocrine stimulatory loop between GHRH and SV1 in primary cancers. Our findings indicate that GHRH analogs could have diagnostic and therapeutic applications for the management of breast cancer.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
V. Pandey, J. K. Perry, K. M. Mohankumar, X.-J. Kong, S.-M. Liu, Z.-S. Wu, M. D. Mitchell, T. Zhu, and P. E. Lobie
Autocrine Human Growth Hormone Stimulates Oncogenicity of Endometrial Carcinoma Cells
Endocrinology, August 1, 2008; 149(8): 3909 - 3919.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, and G. Halmos
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel
PNAS, February 6, 2007; 104(6): 1943 - 1946.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Z. Rekasi, T. Czompoly, A. V. Schally, F. Boldizsar, J. L. Varga, M. Zarandi, T. Berki, R. A. Horvath, and P. Nemeth
Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway
PNAS, March 1, 2005; 102(9): 3435 - 3440.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.